ClinicalTrials.gg
Not yet recruitingNCT06691308Updated Nov 18, 2024

WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients

An Early Phase 1 interventional study of WL276 CAR-T cells in Recurrent or Progressive Glioblastoma, sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-18.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. (part of Imunopharm Technology Co., Ltd.) · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Clinical study evaluating the safety and efficacy of WL276 CAR-T cell therapy in CD276 positive recurrent or progressive glioblastoma patients

Read the detailed description

This study is an open label, single center early exploratory clinical trial of WL276001 CAR-T cell therapy for CD276 positive recurrent or progressive glioblastoma patients. This study used an improved "3+3" experimental design for dose escalation to explore the safety and efficacy of in-situ administration of WL276001 CAR-T cells.

02

Conditions studied

  • Recurrent or Progressive Glioblastoma

Browse trials for

Keywords

  • WL276 CAR-T cells
  • CD276 positive
03

In context

Lead sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd. is the lead sponsor of 27 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with glioblastoma through histopathological examination;
  2. Patients with unresectable recurrent or progressive glioblastoma who have failed or are intolerant to standard treatment; 8.1The standardized systematic treatment received by patients must comply with the 2022 edition of the "Guidelines for the Treatment of Gliomas"; 8.2Requirements for treating intolerance: Refers to patients who are unable to continue the current effective systemic standardized treatment due to toxic side effects such as vomiting, diarrhea, abdominal pain, bone marrow suppression, etc. of grade ≥ 3. Refusal due to economic or personal reasons is not accepted;
  3. Age ≥ 18 years old, including boundary values;
  4. Expected survival period greater than 2 months;
  5. There is at least one measurable intracranial lesion that meets the criteria of Neuro Tumor Response Evaluation (RANO);
  6. Patients must provide tumor samples within 2 years that meet the requirements (paraffin blocks or unstained sections with a quantity that meets the testing requirements specified in this study) and have positive CD276 expression detected by immunohistochemistry;
  7. (KPS) functional status score ≥ 60 points;
  8. Blood routine:

    8.1Hemoglobin () ≥ 90g/L; 8.2Absolute (ANC) ≥ 1.5 × 10 \^ 9/L; 8.3Platelet count () ≥ 70 × 10 \^ 9/L; 8.4Absolute value of lymphocytes ≥ 0.5 × 10 \^ 9/L;

  9. The liver, kidney, heart, and lung functions meet the following requirements:

    9.1Creatinine clearance rate ≥ 60ml/min; 9.2Alanine transaminase () and aspartate transaminase 9.3Aspartate aminotransferase (AST) ≤ 2.5 × , total (TBL) ≤ 1.5 × ULN (for the elevation of ALT and AST that can be explained by liver invasion, AST and ALT high limit can be upregulated up to 5-fold, and TBL high limit can be upregulated up to 3-fold); 9.4Serum albumin ≥ 3.0g/dL; 9.5Left ventricular ≥ 50%, no pericardial effusion [ECHO (Echocardiography, ECHO) examination], no (Electrocardiogram, ECG) results; 9.6Blood oxygen saturation is greater than 95% under non oxygen inhalation conditions.

  10. Women of childbearing age who have a negative blood pregnancy test before the start of the trial and agree to take effective measures during the trial period until the last follow-up; Male participants with reproductive partners agree to take effective contraceptive measures during the trial period until the last follow-up;
  11. Those who voluntarily participate in this experiment and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Those who require the use of ; Or individuals with diseases;
  2. Patients who have received or are waiting for organ transplantation in the past;
  3. The toxicity caused by previous treatment has not stabilized or recovered to ≤ level 1 (except for cases judged by the researcher to be clinically insignificant);
  4. There is a large amount of uncontrollable serosal fluid accumulation (such as pleural effusion, abdominal effusion, pericardial effusion) after treatment;
  5. Use any of the following drugs or treatment methods within the specified time before cell collection:

    5.1Used therapeutic doses of within one week prior to cell collection. But the use of topical and inhaled steroids is allowed; 5.2Received chemotherapy drugs within one week prior to cell collection. If the oral chemotherapy drug has passed at least 3 half lives before cell collection, it is allowed to be included in the group; 5.3Individuals who use drugs to stimulate bone marrow hematopoietic cell production within 5 days prior to cell collection;

  6. CNS diseases that have clinical significance in the past or screening, and have been assessed by researchers as having safety risks;
  7. Individuals who have previously used any gene therapy products;
  8. Active or virus is defined as: subjects who are positive for hepatitis B B virus surface antigen (HBsAg) or hepatitis B B core antibody (HBcAb) and whose peripheral blood HBV DNA titer is higher than the upper limit of detection; Individuals with positive hepatitis C virus (HCV) antibodies and positive peripheral blood HCV RNA (HCV RNA); People infected with AIDS virus and syphilis;
  9. Active EBV and cytomegalovirus are defined as patients with positive or negative IgM antibodies in EBV serum but EBV-DNA levels higher than normal; Patients with IgM antibody positive or IgM antibody negative but CMV-DNA higher than normal in the serum of cytomegalovirus (CMV);
  10. Used the research drug within 4 weeks prior to cell collection. But if the experimental treatment is ineffective or if the disease progresses, and at least 5 half lives have passed before cell collection, it is allowed to be included in the group;
  11. Received radiation therapy within 4 weeks prior to cell collection;
  12. Patients who have undergone major surgical procedures or significant trauma within 4 weeks prior to cell collection, or who are expected to undergo major surgery during the study period;
  13. If immunotherapy such as anti-PD1 and has been used before cell infusion, at least 5 half lives must be passed between the last dose and CAR-T cell infusion;
  14. Abnormal cardiac function includes: long syndrome or QTc interval>480 ms; Complete left bundle branch block, grade II/III atrioventricular block; Severe and uncontrolled arrhythmias requiring medication treatment; History of chronic congestive heart failure and ≥ 3 (refer to Appendix 4) with a heart below 50% within the 6 months prior to screening; Heart valve disease with ≥ 3 grade; Within the first 6 months of screening, there has been a history of myocardial infarction, cardiac angioplasty or stent implantation, unstable angina, severe pericardial disease, or other heart diseases;
  15. Patients who require anticoagulant therapy;
  16. Patients requiring long-term antiplatelet therapy;
  17. Start screening for symptomatic history of venous thrombosis or pulmonary embolism within the previous 6 months;
  18. History of malignant tumors other than non melanoma skin cancer or carcinoma in situ (such as cervical, bladder, breast) (unless in a disease-free state for at least 3 years);
  19. Infections (fungal, bacterial, viral, or other) that require intravenous injection of antibiotics for control or are uncontrollable, such as simple urinary tract infections and bacterial pharyngitis, can be included if the researcher evaluates that they can be controlled through treatment;
  20. Unable to perform MRI examination (such as installing pacemakers, metal dentures, etc.)
  21. The researcher shall determine whether the patient has any factors that affect compliance with the protocol, or is unwilling or unable to comply with the procedures required in the research protocol.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    CD276 positive recurrent or progressive glioblastoma

    Inject WL276 CAR-T cells through local intracranial administration using the Ommaya device, once a week for 3 weeks. After 3 weeks of continuous administration, perform cranial MRI imaging to evaluate tumor progression and assess drug efficacy. Propose to deliver doses of 5 \* 10 \^ 6 CAR-T Cells and 1 \* 10 \^ 7 CAR-T Cells in sequence, with 3 subjects enrolled in each dose group

    Combination Product: WL276 CAR-T cells

Interventions

  • Combination productWL276 CAR-T cells

    This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses

06

What researchers measure

Primary outcomes

  1. Evaluate the safety(Adverse event incidence rate、Incidence rate of abnormal laboratory test results) and tolerability(DLT incidence rate) of WL276 CAR-T cell therapy for CD276 positive recurrent or progressive glioblastoma

    Adverse events related to CAR-T cell therapy within 28 days after infusion, abnormal laboratory test results with clinical significance, including dose limiting toxicity (DLTs).

    Time frame: Within 28 days after infusion

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression Free Survival (PFS) after infusion.

    Time frame: 720 days after infusion

  2. Overall Survival (OS)

    Overall Survival (OS) after infusion.

    Time frame: 720 days after infusion

Other outcomes

  1. incidence of adverse events

    Collect and compare the safety (incidence of adverse events) of different administration methods

    Time frame: 720 days after infusion

  2. disease improvement rate

    Collect and compare the efficacy (disease improvement rate) of different administration methods

    Time frame: 720 days after infusion

  3. CAR-T cell counting

    Collect and compare cell expansion data (CAR-T cell counts) after different administration methods

    Time frame: 720 days after infusion

  4. CAR-T cell survival rate

    Retention of WL276 CAR-T cells in peripheral blood, cerebrospinal fluid, and/or tumor tissue of patients

    Time frame: 720 days after infusion

  5. CAR-T cell survival time

    Duration of WL276 CAR-T cells in peripheral blood, cerebrospinal fluid, and/or tumor tissue of patients

    Time frame: 720 days after infusion

  6. Cytokine levels

    Changes in cytokines in peripheral blood of subjects before and after infusion of WL276 CAR-T cells, as well as the time to return to normal

    Time frame: 720 days after infusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for May 2027, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 15, 2024
StartEst.
Nov 12, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06691308
Responsible party
Sponsor
First posted
Nov 15, 2024
Start date
Nov 12, 2024 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 18, 2024

Study contacts

yanping Ding, doctorate
Contact
dingyanping@imunopharm.com
01062886890
gang Cheng, doctorate
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion